EU Centralised Authorisation of BioNet’s Pertussis‑Only Vaccine Medicines intended for use across the European Union may be assessed through the centralised authorisation procedure coordinated by the European Medicines Agency. BioNet pertussis-only vaccine was evaluated under this framework to ensure a harmonised…

Role of Pertussis Booster Vaccination in EU Immunisation Strategies Booster vaccination plays a central role in pertussis prevention across the European Union. While primary vaccination provides early protection, immunity wanes over time, underscoring the importance of booster doses for adolescents, adults,…

An Alternative to Pertussis Combination Vaccines for Booster Use Combination vaccines containing pertussis, tetanus, and diphtheria antigens have played a central role in pertussis prevention for many years. However, not all individuals requiring pertussis booster vaccination need repeated immunisation against tetanus…

Maternal Immunisation and Passive Protection of Newborns Maternal vaccination is a proven way to protect young babies from pertussis (whooping cough) during their first months of life, before they finish their primary vaccination series. BioNet’s pertussis‑only vaccine is approved for use…

A Focused Strategy Against Pertussis Toxin Pertussis toxin is a central virulence factor of Bordetella pertussis and is closely associated with the severe clinical manifestations of whooping cough. The scientific rationale for BioNet’s pertussis-only vaccine is based on inducing immune responses…

Pertussis-Only Booster Vaccine Receives EU Marketing Authorisation For many individuals, protection against pertussis remains important, while booster vaccination against tetanus and diphtheria may not always be required at the same time. BioNet has developed a pertussis-only vaccine that has received Marketing…

Clinical Evidence Supporting EU Authorisation The Marketing Authorisation of BioNet’s pertussis-only vaccine is supported by a comprehensive clinical development programme reviewed by the Committee for Medicinal Products for Human Use (CHMP). The assessment included data from three main randomised controlled clinical…

EU-Authorised Pertussis-Only Booster Vaccine for Healthcare Professionals Healthcare professionals are among the population groups with increased potential exposure to pertussis. In many healthcare settings, booster vaccination is recommended at regular intervals to help maintain protection and reduce the risk of transmission…

EU-Authorised Pertussis Booster Vaccination for Teenagers Teenagers play an important role in the transmission dynamics of pertussis. As immunity acquired through early childhood vaccination gradually wanes, adolescents may become susceptible again. In this age group, pertussis infection can present with mild…

The European Commission Grants Marketing Authorisation for a First-of-its-Kind Pertussis-Only Vaccine for Vaccination of Teenagers, Adults and Pregnant Women in the European Union Europeans in the European Union (EU) may soon have the choice to get vaccinated against whooping cough with…